CA3028348A1 - Method for electrochemical analysis by use of alternating output signals from two electrodes - Google Patents
Method for electrochemical analysis by use of alternating output signals from two electrodes Download PDFInfo
- Publication number
- CA3028348A1 CA3028348A1 CA3028348A CA3028348A CA3028348A1 CA 3028348 A1 CA3028348 A1 CA 3028348A1 CA 3028348 A CA3028348 A CA 3028348A CA 3028348 A CA3028348 A CA 3028348A CA 3028348 A1 CA3028348 A1 CA 3028348A1
- Authority
- CA
- Canada
- Prior art keywords
- input signal
- excitations
- electrode
- sample
- analyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 278
- 238000000840 electrochemical analysis Methods 0.000 title description 2
- 239000012491 analyte Substances 0.000 claims abstract description 251
- 230000005284 excitation Effects 0.000 claims abstract description 221
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 94
- 239000000523 sample Substances 0.000 claims description 311
- 230000004044 response Effects 0.000 claims description 167
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 133
- 239000008103 glucose Substances 0.000 claims description 133
- 230000000694 effects Effects 0.000 claims description 77
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- 238000007254 oxidation reaction Methods 0.000 claims description 30
- 230000003647 oxidation Effects 0.000 claims description 29
- 238000000926 separation method Methods 0.000 claims description 24
- 125000002015 acyclic group Chemical group 0.000 claims description 16
- 238000004364 calculation method Methods 0.000 claims description 14
- 239000012472 biological sample Substances 0.000 claims description 13
- 238000006479 redox reaction Methods 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- 238000012806 monitoring device Methods 0.000 claims description 9
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 claims description 5
- 235000019420 glucose oxidase Nutrition 0.000 claims description 4
- 108090000854 Oxidoreductases Proteins 0.000 claims description 3
- 102000004316 Oxidoreductases Human genes 0.000 claims description 3
- 210000003722 extracellular fluid Anatomy 0.000 claims description 3
- 210000002977 intracellular fluid Anatomy 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 241000894007 species Species 0.000 description 165
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 130
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 65
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 65
- 238000005259 measurement Methods 0.000 description 62
- 230000006870 function Effects 0.000 description 49
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 48
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 48
- 229940116269 uric acid Drugs 0.000 description 48
- 238000005534 hematocrit Methods 0.000 description 45
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 40
- 238000012360 testing method Methods 0.000 description 37
- 238000004458 analytical method Methods 0.000 description 33
- 239000000243 solution Substances 0.000 description 33
- 230000008569 process Effects 0.000 description 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 21
- 108090000790 Enzymes Proteins 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 21
- 235000010323 ascorbic acid Nutrition 0.000 description 21
- 229960005070 ascorbic acid Drugs 0.000 description 21
- 239000011668 ascorbic acid Substances 0.000 description 21
- 229940088598 enzyme Drugs 0.000 description 21
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 21
- 238000012937 correction Methods 0.000 description 20
- 229960005489 paracetamol Drugs 0.000 description 20
- QNBVYCDYFJUNLO-UHDJGPCESA-N [(e)-(1-methylpyridin-2-ylidene)methyl]-oxoazanium;iodide Chemical compound [I-].CN1C=CC=C\C1=C/[NH+]=O QNBVYCDYFJUNLO-UHDJGPCESA-N 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 229960002095 pralidoxime iodide Drugs 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 238000001514 detection method Methods 0.000 description 16
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 230000008901 benefit Effects 0.000 description 12
- 239000013060 biological fluid Substances 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 238000001075 voltammogram Methods 0.000 description 12
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000006399 behavior Effects 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 238000005070 sampling Methods 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 6
- 238000003869 coulometry Methods 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 238000003487 electrochemical reaction Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000007988 ADA buffer Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000004082 amperometric method Methods 0.000 description 5
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000002277 temperature effect Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 238000000835 electrochemical detection Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000002848 electrochemical method Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940085991 phosphate ion Drugs 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000004832 voltammetry Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000006056 electrooxidation reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000009594 malabsorption test Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
- G01N27/3274—Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662361358P | 2016-07-12 | 2016-07-12 | |
| US62/361,358 | 2016-07-12 | ||
| US201662430232P | 2016-12-05 | 2016-12-05 | |
| US62/430,232 | 2016-12-05 | ||
| PCT/IB2017/054133 WO2018011692A1 (en) | 2016-07-12 | 2017-07-07 | Method for electrochemical analysis by use of alternating output signals from two electrodes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3028348A1 true CA3028348A1 (en) | 2018-01-18 |
Family
ID=59593132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3028348A Abandoned CA3028348A1 (en) | 2016-07-12 | 2017-07-07 | Method for electrochemical analysis by use of alternating output signals from two electrodes |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11268925B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3485265B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7066673B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109690304A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3028348A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018011692A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3028348A1 (en) | 2016-07-12 | 2018-01-18 | Ascensia Diabetes Care Holdings Ag | Method for electrochemical analysis by use of alternating output signals from two electrodes |
| JP7074753B2 (ja) * | 2016-12-05 | 2022-05-24 | アセンシア・ダイアベティス・ケア・ホールディングス・アーゲー | リスク因子モニタリング |
| US11959872B2 (en) | 2018-03-19 | 2024-04-16 | Phc Holdings Corporation | Method for measuring amount of blood component in blood |
| EP3920798B1 (en) * | 2019-02-05 | 2024-08-14 | Ascensia Diabetes Care Holdings AG | Apparatus and methods for probing sensor operation of continuous analyte sensing and auto-calibration |
| EP3972493B1 (en) * | 2019-05-21 | 2024-10-16 | Ascensia Diabetes Care Holdings AG | Compensation system and method for thermistor sensing in an analyte biosensor |
| WO2022010620A1 (en) * | 2020-07-08 | 2022-01-13 | Abbott Diabetes Care Inc. | Analyte sensors featuring enhancements for decreasing interferent signal |
| CN111948271B (zh) * | 2020-07-24 | 2022-07-12 | 北京航空航天大学 | 一种调控电极电势强化微生物电化学系统检测水体水质生物毒性的方法 |
| JP7781686B2 (ja) * | 2022-03-17 | 2025-12-08 | アークレイ株式会社 | バイオセンサを用いた酸化還元酵素の電気化学的測定方法及びそれに用いるバイオセンサ |
| CN120232968A (zh) * | 2023-12-28 | 2025-07-01 | 江苏鱼跃凯立特生物科技有限公司 | 一种测试生物样品中分析物的方法、传感器及系统 |
| CN120232969A (zh) * | 2023-12-28 | 2025-07-01 | 江苏鱼跃凯立特生物科技有限公司 | 一种区分质控液与生物样品的方法 |
| CN120232970A (zh) * | 2023-12-28 | 2025-07-01 | 江苏鱼跃凯立特生物科技有限公司 | 一种血糖浓度计算方法及传感器 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2571929T3 (es) | 2004-05-26 | 2016-05-27 | Region Nordjylland | Procedimiento para determinar la cantidad de CD36 circulante |
| TW200641352A (en) | 2005-04-08 | 2006-12-01 | Bayer Healthcare Llc | Oxidizable species as an internal reference in control solutions for biosensors |
| KR101503072B1 (ko) | 2005-07-20 | 2015-03-16 | 바이엘 헬스케어 엘엘씨 | 게이트형 전류 측정법 |
| US8404100B2 (en) * | 2005-09-30 | 2013-03-26 | Bayer Healthcare Llc | Gated voltammetry |
| JP5395665B2 (ja) * | 2006-09-22 | 2014-01-22 | バイエル・ヘルスケア・エルエルシー | 改善された安定性およびヘマトクリット性能（ｐｅｒｆｏｒｍａｎｃｅ）を有するバイオセンサー系 |
| EP2679150B1 (en) | 2006-10-24 | 2020-07-22 | Ascensia Diabetes Care Holdings AG | Transient decay amperometry |
| EP2535704B1 (en) * | 2007-09-24 | 2015-09-09 | Bayer HealthCare LLC | Multi-electrode test method |
| EP2222867B1 (en) | 2007-12-10 | 2018-07-11 | Ascensia Diabetes Care Holdings AG | Rapid-read gated amperometry |
| JP5812603B2 (ja) | 2007-12-10 | 2015-11-17 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ | 勾配ベース補正 |
| CN105353013B (zh) | 2008-07-10 | 2020-01-14 | 安晟信医疗科技控股公司 | 识别样本中的电离物质的方法 |
| CN102239406A (zh) * | 2008-12-08 | 2011-11-09 | 拜尔健康护理有限责任公司 | 具有信号调节功能的生物传感器系统 |
| CN103003692B (zh) | 2010-03-22 | 2015-01-14 | 拜尔健康护理有限责任公司 | 用于生物传感器的剩余补偿 |
| EP2577303B1 (en) | 2010-06-07 | 2022-08-03 | Ascensia Diabetes Care Holdings AG | Underfill management system for a biosensor |
| EP3104176B1 (en) | 2010-06-07 | 2018-08-29 | Ascensia Diabetes Care Holdings AG | Slope-based compensation including secondary output signals |
| US8615366B2 (en) | 2010-10-15 | 2013-12-24 | Roche Diagnostics Operations, Inc. | Handheld diabetes management device with bolus calculator |
| EP3315123B1 (en) * | 2011-09-21 | 2019-08-21 | Ascensia Diabetes Care Holdings AG | Analysis compensation including segmented signals |
| US20130116526A1 (en) | 2011-11-09 | 2013-05-09 | Telcare, Inc. | Handheld Blood Glucose Monitoring Device with Messaging Capability |
| EP3269304B1 (en) | 2012-07-27 | 2020-10-07 | Ascensia Diabetes Care Holdings AG | System and method for detecting used and dried sensors |
| GB2505694B (en) * | 2012-09-07 | 2017-03-22 | Lifescan Scotland Ltd | Electrochemical-based analytical test strip with bare interferent electrodes |
| US9244036B2 (en) | 2012-11-16 | 2016-01-26 | Cilag Gmbh International | System and method for determination of a concentration of at least one interfering substance and correction of glucose concentration based on the concentration of the interfering substance |
| EP3537141A1 (en) * | 2012-12-12 | 2019-09-11 | PHC Holdings Corporation | Blood component measuring device and method for measuring blood component |
| US9958410B2 (en) | 2013-03-14 | 2018-05-01 | Ascensia Diabetes Care Holdings Ag | Normalized calibration of analyte concentration determinations |
| CN105190299B (zh) * | 2013-03-15 | 2018-04-20 | 豪夫迈·罗氏有限公司 | 电化学测量分析物的基于描述符的方法以及结合该方法的设备、装置和系统 |
| CN105143870B (zh) * | 2013-04-26 | 2018-03-20 | 松下健康医疗控股株式会社 | 液体试样测定装置、液体试样测定方法以及生物传感器 |
| EP3021112B1 (en) * | 2013-07-08 | 2022-01-05 | PHC Holdings Corporation | Blood component measurement device and blood component measurement method |
| US11185468B2 (en) | 2014-04-28 | 2021-11-30 | The Regents Of The University Of California | Unobtrusive wireless electronic systems for monitoring and facilitating patient compliance |
| PL3597765T3 (pl) * | 2014-08-25 | 2021-11-08 | F. Hoffmann-La Roche Ag | Pasek testowy z dwoma elektrodami kompensujący zakłócenie |
| CA3028348A1 (en) | 2016-07-12 | 2018-01-18 | Ascensia Diabetes Care Holdings Ag | Method for electrochemical analysis by use of alternating output signals from two electrodes |
-
2017
- 2017-07-07 CA CA3028348A patent/CA3028348A1/en not_active Abandoned
- 2017-07-07 CN CN201780055995.3A patent/CN109690304A/zh active Pending
- 2017-07-07 WO PCT/IB2017/054133 patent/WO2018011692A1/en not_active Ceased
- 2017-07-07 JP JP2019501453A patent/JP7066673B2/ja active Active
- 2017-07-07 US US16/316,589 patent/US11268925B2/en active Active
- 2017-07-07 EP EP17751841.2A patent/EP3485265B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018011692A1 (en) | 2018-01-18 |
| US11268925B2 (en) | 2022-03-08 |
| JP7066673B2 (ja) | 2022-05-13 |
| EP3485265A1 (en) | 2019-05-22 |
| JP2019521343A (ja) | 2019-07-25 |
| US20190293594A1 (en) | 2019-09-26 |
| CN109690304A (zh) | 2019-04-26 |
| EP3485265B1 (en) | 2025-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11268925B2 (en) | Intertwined electrical input signals | |
| US20200348306A1 (en) | Slope-Based Compensation | |
| RU2491549C2 (ru) | Амперометрия со стробированием и быстрым считыванием | |
| RU2238548C2 (ru) | Способ измерения концентрации анализируемого вещества (варианты), измерительный прибор для измерения концентрации анализируемого вещества | |
| EP3104176B1 (en) | Slope-based compensation including secondary output signals | |
| EP3901624B1 (en) | Methods to compensate for sources of error during electrochemical testing | |
| MX2012014281A (es) | Sitema de gestionde llenado insuficiente para un biosensor. | |
| US11353417B2 (en) | Risk factor monitoring | |
| KR20120099452A (ko) | 바이오센서용 언더필 인식 시스템 | |
| HK40006914A (en) | Method for electrochemical analysis by use of alternating output signals from two electrodes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230109 |
|
| FZDE | Discontinued |
Effective date: 20230109 |
|
| FZDE | Discontinued |
Effective date: 20230109 |